List of Excipients in Branded Drug AMMONIA N-13

Generic Drugs Containing AMMONIA N-13

Company	Ingredient	NDC	Excipient
Brigham and Women's Hospital Inc The	ammonia n-13	24450-113	SODIUM CHLORIDE
Precision Nuclear LLC	ammonia n-13	52768-100	SODIUM CHLORIDE
The Methodist Hospital Research Institute	ammonia n-13	69864-002	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in AMMONIA N-13?

# Of NDCs	Excipient
3	SODIUM CHLORIDE

Ammonia N-13 Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Ammonia N-13 is a short-lived PET radiopharmaceutical used primarily for myocardial perfusion imaging. Its commercial value is driven by cyclotron access, production reliability, radiochemical quality, distribution radius, automated compounding, and cardiac-PET reimbursement rather than by conventional excipient differentiation. The isotope has a physical half-life of approximately 9.96 minutes, which sharply limits shelf life and favors local or on-site manufacturing.[1]

What is Ammonia N-13 used for?

Ammonia N-13 Injection is an FDA-approved diagnostic radiopharmaceutical for positron emission tomography of the myocardium under rest and pharmacologic or exercise stress conditions. It is used to assess myocardial perfusion and support the evaluation of coronary artery disease.[1]

Attribute	Ammonia N-13
Active radioactive component	Nitrogen-13-labeled ammonia
Primary use	Myocardial perfusion PET
Administration	Intravenous injection
Physical half-life	Approximately 9.96 minutes
Production	Medical cyclotron, generally through a proton-induced nuclear reaction
Dosage form	Sterile injectable solution
Main commercial constraint	Extremely short distribution and use window
Primary competitors	Rubidium-82, N-13 ammonia, F-18 flurpiridaz, SPECT perfusion agents
Regulatory category	Diagnostic radiopharmaceutical
Biosimilar relevance	None
Conventional generic model	Limited; production and facility capability are central

The short half-life means that N-13 ammonia cannot be manufactured at a remote facility and distributed nationally in the manner of a conventional injectable drug. A production site must be located close enough to the imaging center, or the imaging center must have an integrated cyclotron and radiopharmacy operation.

What excipients are used in Ammonia N-13 Injection?

The principal excipient strategy is a simple sterile aqueous vehicle, generally based on sodium chloride injection or another isotonic aqueous medium suitable for intravenous administration. The commercial objective is to minimize chemical and radiochemical interactions rather than to create a differentiated formulation platform.[1]

Core excipient requirements

An N-13 ammonia formulation should address:

1. Sterility and bacterial endotoxin control.
2. Physiologic or near-physiologic osmolality.
3. Acceptable pH for intravenous administration.
4. Low metal-ion contamination.
5. Compatibility with the radionuclide, precursor chemistry, transfer lines, syringes, and dose calibrators.
6. Low particulate burden.
7. Rapid release testing compatible with the 9.96-minute half-life.

A conventional preservative is generally unattractive because the product is administered as a sterile single-use radiopharmaceutical and is typically prepared in small, patient-specific quantities. Preservatives can introduce toxicity, compatibility, or regulatory complexity without improving commercial value.

Excipient categories and strategic assessment

Excipient category	Strategic role	Commercial assessment
Sodium chloride	Isotonic vehicle	Established, low differentiation
Water for injection	Solvent	Required manufacturing component
Buffer system	pH control	Potentially useful, but must not impair radiochemical purity
Chelator	Controls trace metals or radionuclide chemistry	Technically interesting, but may alter biodistribution and requires substantial validation
Antioxidant	Limits oxidative degradation	Possible in process development, but clinical value must be demonstrated
Preservative	Multidose microbial control	Generally unattractive for short-lived single-dose product
Surfactant	Prevents adsorption or improves transfer	Usually unnecessary unless device or container interactions arise
Bulking agent	Not normally needed for a liquid injectable	Low value
Container coating	Reduces adsorption or leachables	More commercially relevant than a new bulk excipient

The highest-value formulation work is likely to involve container-closure systems, tubing materials, automated synthesis cartridges, and transfer components. These can reduce adsorption, residual contamination, dose loss, and operator exposure without changing the fundamental formulation.

How does the N-13 ammonia formulation affect commercial value?

Excipient optimization has a limited effect on the isotope's physical half-life. A better formulation cannot create a conventional multi-day shelf life. Its commercial value instead comes from reducing operational losses and increasing the percentage of produced activity that reaches the patient.

A formulation or process improvement may create value by:

• increasing recovered activity at the end of synthesis;
• reducing decay during purification and release testing;
• improving reproducibility between production batches;
• shortening quality-control release time;
• reducing dose loss in syringes and administration sets;
• maintaining radiochemical purity during the clinical-use window;
• supporting higher-throughput cardiac PET scheduling;
• improving compatibility with automated dispensing systems.

For N-13 ammonia, a 5% to 10% improvement in usable patient doses can be more commercially meaningful than a conventional excipient patent with no impact on workflow. Revenue depends on doses delivered before decay, not simply on the volume of bulk solution manufactured.

What manufacturing and excipient barriers protect N-13 ammonia?

The main barriers are manufacturing and operational rather than formulation exclusivity.

Cyclotron production

N-13 ammonia is generally produced using a medical cyclotron. The required infrastructure includes:

• a cyclotron capable of the relevant proton irradiation;
• an enriched-water or related target system;
• automated synthesis equipment;
• shielded hot cells;
• sterile filtration and dispensing systems;
• radiochemical and radionuclidic purity testing;
• validated environmental and aseptic controls;
• trained radiation and pharmacy personnel.

The short half-life makes process efficiency critical. A synthesis that takes several minutes longer can materially reduce the activity available for patient dosing.

Process-control opportunities

Commercially defensible improvements may include:

• automated target transfer;
• faster conversion of produced N-13 into injectable ammonia;
• lower-volume purification;
• integrated sterile filtration;
• real-time or near-real-time radiochemical monitoring;
• automated dose dispensing;
• closed-system transfer devices;
• low-dead-volume tubing and syringes;
• software that coordinates production with scheduled scans.

These improvements can be protected through process patents, equipment claims, software claims, trade secrets, or customer-specific validation packages. The strongest protection is likely to be a combination of proprietary process know-how and installed workflow infrastructure.

What patents protect Ammonia N-13?

The core molecule, ammonia, and the use of nitrogen-13 as a PET radionuclide are unlikely to provide meaningful current composition-of-matter exclusivity. Any early patents covering N-13 ammonia production, myocardial perfusion imaging, or basic radiopharmaceutical use would generally face significant age and expiration constraints.

Current protection is more likely to arise from:

• automated synthesis methods;
• precursor and target configurations;
• purification systems;
• radiopharmaceutical production modules;
• container and transfer-device designs;
• quality-control methods;
• imaging protocols;
• kinetic modeling and quantification software;
• combination claims involving N-13 ammonia and cardiac stress agents.

A definitive patent-by-patent freedom-to-operate conclusion cannot be inferred from the product name alone. Patent risk must be assessed by searching relevant claims across the United States, Europe, Japan, China, and other jurisdictions where cyclotron and cardiac-PET businesses operate.

Patent-strength assessment

Asset type	Likely current strength	Commercial relevance
N-13 ammonia composition	Low	Core molecule and isotope use are old technologies
Basic myocardial perfusion indication	Low to moderate	Depends on claim scope and expiration
Automated synthesis	Moderate to high	Can protect workflow and production economics
Target and precursor systems	Moderate	Useful where design materially improves yield
Excipient composition	Low to moderate	Strong only if it improves stability or manufacturing performance
Container and transfer system	Moderate	Relevant to dose recovery and operator safety
Imaging quantification software	Moderate to high	Can create recurring revenue and lock-in
Manufacturing trade secrets	High in practice	Difficult for competitors to replicate quickly

What is the FDA regulatory status of Ammonia N-13?

Ammonia N-13 Injection is regulated as a prescription diagnostic radiopharmaceutical. The FDA-approved labeling addresses myocardial PET imaging, administration, radiation exposure, preparation, and handling requirements.[1]

Radiopharmaceutical manufacturing must comply with applicable current good manufacturing practice requirements. Facilities also face federal and state radiation-control obligations, radioactive-material licensing, aseptic processing requirements, and quality-system controls.[2]

The key regulatory distinction is that N-13 ammonia is manufactured close to the point of use. A commercial product therefore requires more than an approved formulation. It requires a validated production network or an integrated cyclotron model capable of reliably producing and releasing the product within its use window.

What is the Orange Book status of Ammonia N-13?

The Orange Book is relevant only if an approved drug product has listed patents or exclusivity that affect an abbreviated approval pathway. For a short-lived radiopharmaceutical such as N-13 ammonia, the commercial relevance of Orange Book-listed patents is generally lower than for conventional small-molecule drugs because the principal barriers involve site capability, manufacturing controls, and logistics.[3]

A competitor should distinguish among:

• FDA approval of the radiopharmaceutical;
• local production under an approved application or applicable radiopharmaceutical pathway;
• patent-listed claims in the Orange Book;
• patents covering manufacturing equipment or methods;
• facility-specific regulatory approvals.

Patent listings, if any, should be verified directly in the current FDA Orange Book and Drugs@FDA records before a Paragraph IV strategy is evaluated.[3,4]

When does Ammonia N-13 lose exclusivity?

The practical exclusivity period for N-13 ammonia is not defined solely by a single patent expiration date. The drug's basic technology is mature, and commercial entry is constrained by production infrastructure.

Potential exclusivity categories include:

Exclusivity category	Likely significance
New chemical entity exclusivity	Not expected to be a current commercial driver for this mature radionuclide
Orphan-drug exclusivity	Not the normal basis for myocardial perfusion PET
Pediatric exclusivity	Not a central commercial factor
Formulation patents	Possible, but narrow and technically dependent
Method-of-use patents	Possible, particularly for imaging protocols or selected populations
Process patents	Potentially relevant to yield, automation, or purification
Trade secrets	Important for local production reliability
Facility and licensing barriers	Often more significant than patent term

The practical opportunity for a new entrant is therefore to provide an equivalent or superior production and delivery system, not simply to reproduce the labeled formulation.

Are there Paragraph IV challenges or generic-entry risks?

A Paragraph IV challenge is commercially plausible only where an applicant relies on an applicable abbreviated pathway and identifies a listed patent as invalid, unenforceable, or not infringed. The existence of a marketed N-13 ammonia product does not by itself establish an active Paragraph IV opportunity.

Generic-entry risk is better analyzed through four questions:

1. Is there an approved reference product with relevant listed patents?
2. Can the entrant establish pharmaceutical equivalence and radiochemical equivalence?
3. Can the entrant produce and release doses within the short radioactive-use window?
4. Does the entrant have local cyclotron capacity and hospital distribution access?

The fourth question is usually decisive. A nominally open formulation market may still be difficult to enter because a competitor must build or contract for production capacity near each customer cluster.

Which companies are challenging the N-13 ammonia market?

The competitive landscape includes radiopharmaceutical manufacturers, hospital-based cyclotron programs, academic medical centers, radiopharmacy networks, and PET equipment providers. Competition is local because transportation distance and decay impose geographic limits.

Principal competitive categories

Competitor	Competitive position
Rubidium-82 providers	Generator-based myocardial perfusion alternative with different workflow and cost profile
F-18 flurpiridaz developers and suppliers	Longer-lived PET myocardial perfusion alternative with broader distribution potential
SPECT technetium agents	Lower infrastructure burden and broad installed-base access
Hospital cyclotron programs	Local N-13 production and control over scheduling
Commercial radiopharmacies	Regional production, logistics, and customer-service scale
PET scanner manufacturers	Workflow integration, quantitative imaging, and software differentiation

F-18 flurpiridaz is the most strategically important potential comparator because its longer half-life could support wider distribution and more flexible scheduling than N-13 ammonia. Rubidium-82 has a different advantage: a generator-based supply model that avoids the need for an on-site cyclotron, although it has its own cost, radiation, and operational constraints.[5]

How does Ammonia N-13 compare with Rubidium-82 and F-18 flurpiridaz?

Factor	N-13 ammonia	Rubidium-82	F-18 flurpiridaz
Production model	Cyclotron	Generator	Cyclotron
Half-life	About 9.96 minutes	About 75 seconds	About 110 minutes
Distribution	Highly local	Generator-centered	Potentially regional or national
Excipient differentiation	Limited	Limited	Greater opportunity for finished-product formulation
Infrastructure	Cyclotron and synthesis module	Generator and PET facility	Cyclotron or regional radiopharmacy
Commercial strength	High where local cardiac PET is established	Strong where generator economics work	Potentially strong if regulatory and reimbursement adoption expand
Main risk	Decay and production timing	Generator cost and supply	Development, approval, reimbursement, and manufacturing scale-up

N-13 ammonia can remain attractive where a facility already owns a cyclotron and needs a high-quality myocardial perfusion tracer. Its weakness is the inability to decouple production from scanning operations.

What licensing deals could create value?

The most valuable licensing models are likely to involve systems rather than a single excipient.

Potential deal structures include:

• licensing an automated N-13 synthesis module to hospitals;
• exclusive regional radiopharmacy supply agreements;
• bundled cyclotron, synthesis, QC, and dose-dispensing contracts;
• co-development of low-dead-volume consumables;
• licensing cardiac PET quantification software;
• supply agreements for target components and sterile cassettes;
• service contracts tied to dose availability or scan throughput.

A company with a modest formulation improvement but no manufacturing network may have limited standalone leverage. A company that combines validated production technology, consumables, software, and service support can capture recurring revenue and increase switching costs.

What formulation patents could be commercially valuable?

The most credible patent opportunities are narrow, performance-based claims. Examples include:

• an aqueous N-13 ammonia formulation that maintains radiochemical purity through the full administration window;
• a low-metal formulation that improves synthesis consistency;
• a container-closure system that reduces adsorption and dose loss;
• a sterile transfer assembly that reduces residual activity;
• a formulation compatible with a defined automated dispensing system;
• a process that reduces synthesis time while maintaining sterility and radionuclidic purity.

Broad claims covering "N-13 ammonia in saline" are likely to face prior-art and obviousness challenges. Patent applications should focus on measurable technical effects, such as higher recovered activity, reduced impurity formation, lower residual activity, or improved release speed.

What revenue exposure does N-13 ammonia create?

Revenue exposure is concentrated in institutions with:

• cardiac PET capability;
• sufficient patient volume;
• cyclotron access;
• trained nuclear medicine staff;
• reimbursement support;
• demand for quantitative myocardial blood-flow assessment.

For manufacturers, the largest revenue risks are operational:

• cyclotron downtime;
• failed target runs;
• delayed synthesis;
• missed scan appointments;
• inadequate daily patient volume;
• regulatory shutdowns;
• supply interruptions for enriched target material or disposable cassettes.

For hospitals, the commercial case depends on utilization. A low-volume site may be unable to justify dedicated N-13 infrastructure and may prefer Rubidium-82, SPECT, or outsourced radiopharmacy supply.

Key Takeaways

• N-13 ammonia is a short-lived PET radiopharmaceutical with a half-life of approximately 9.96 minutes.
• Its excipient strategy is intentionally simple: sterile aqueous delivery, physiologic tolerability, low contamination, and rapid release.
• Conventional formulation patents have limited likely value unless they produce measurable improvements in dose recovery, radiochemical purity, or workflow speed.
• The strongest commercial barriers are cyclotron access, automation, quality control, geographic proximity, and scheduling reliability.
• N-13 ammonia has no biosimilar risk because it is a radioactive small-molecule diagnostic agent, not a biologic.
• Paragraph IV risk depends on current FDA patent listings and the applicable abbreviated pathway, not on the existence of a marketed product alone.
• The highest-value opportunities are integrated platforms combining synthesis equipment, sterile consumables, local supply, QC, dose dispensing, and cardiac-PET software.
• F-18 flurpiridaz presents the principal longer-lived PET competitor, while Rubidium-82 remains the main generator-based alternative.

FAQs About Ammonia N-13 Excipient Strategy

Can an excipient extend the shelf life of N-13 ammonia?

No. The dominant shelf-life constraint is the physical decay of nitrogen-13, not chemical instability. Excipient optimization can preserve radiochemical quality during production and administration but cannot materially change the isotope's 9.96-minute half-life.

Is N-13 ammonia suitable for a conventional national radiopharmacy model?

Usually not. Its short half-life favors on-site cyclotron production or tightly localized radiopharmacy distribution. A national distribution model is generally impractical without a dense network of production sites.

Could a chelator improve N-13 ammonia manufacturing?

A chelator could affect trace-metal chemistry or process consistency, but it could also alter chemical speciation, biodistribution, purification, and safety. Any chelator strategy would require full radiochemical, pharmacokinetic, clinical, and regulatory validation.

Does N-13 ammonia compete with F-18 FDG?

Not directly in its primary use. F-18 FDG is principally an oncology and general metabolic imaging agent, while N-13 ammonia is used mainly for myocardial perfusion PET. The more relevant cardiac-PET comparison is with Rubidium-82 and F-18 flurpiridaz.

What is the best IP strategy for a new N-13 ammonia entrant?

The strongest approach is a layered portfolio covering automated synthesis, target configuration, purification, sterile transfer, container compatibility, dose dispensing, imaging quantification, and operational know-how. A standalone broad excipient claim is less likely to create durable commercial protection.

References

1. U.S. Food and Drug Administration. (n.d.). Ammonia N 13 injection: Prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for drugs. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.

5. U.S. Food and Drug Administration. (2021). Flurpiridaz F 18 injection: FDA briefing and clinical development materials. FDA.